ArticleThe ultrasound journal2026
Diagnostic Accuracy of Sonographic Signs of Extrapulmonary Tuberculosis and Treatment Response Monitoring in HIV-Positive and -Negative Populations.
Article in The ultrasound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Diagnosis and monitoring of extrapulmonary tuberculosis (EPTB) remains challenging. Ultrasound such as the extended focused assessment for HIV-associated tuberculosis (eFASH) protocol might improve diagnosis and monitoring of treatment responses. This study determined the diagnostic accuracy of eFASH for EPTB and its value in monitoring EPTB treatment response compared with clinical signs and symptoms. Methods We performed a post-hoc analysis of a trial assessing eFASH impact on management of adults with suspected EPTB. Participants who had baseline and follow-up ultrasound examinations were included. We assessed the diagnostic accuracy of eFASH and compared the evolution of eFASH and clinical signs and symptoms in participants with definite EPTB, stratified by favorable treatment outcomes at 6 months. Results In 296 included participants (95 with definite EPTB, 201 with no definite EPTB), the most common eFASH signs were pleural effusion (47%) and pulmonary B-lines with subpleural granular artefacts (34%). Pleural effusion was the only sign that persisted beyond 6 months. eFASH had a sensitivity of 93.7% (95% CI, 86.8-97.6) and a specificity of 37.8% (95% CI, 31.1- 44.9) for definite EPTB. At 2 months, favorable outcomes were similar between participants with full and partial resolution of eFASH signs (83% versus 81%). In contrast, a higher proportion of favorable outcomes was seen in participants with full resolution of clinical signs and symptoms (90% versus 60%). Conclusion eFASH shows high sensitivity but low specificity for definite EPTB. Ultrasound can be used alongside clinical signs and symptoms to monitor treatment response in patients with EPTB.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.